Xanodyne Cancels IPO

Xanodyne Pharmaceuticals Inc., a Florence, Ky.-based drug company, has withdrawn registration for an $86.25 million IPO due to “market conditions.” It had planned to trade on the Nasdaq, with Morgan Stanley and Deutsche Bank Securities serving as co-lead underwriters.

The company has raised around $232 million in total VC funding, including a $170 million Series A-1 round in 2005 that helped finance the $210 million acquisition of aaiPharma’s pharmaceutical division out of bankruptcy.

Shareholders include Apax Partners (23.2% pre-IPO stake), MPM Capital (21.3%), AIG (10.9%), Essex Woodlands Health Ventures (10.7%), HealthCare Ventures (10.3%), Aisling Capital (9.5%) and Blue Chip Venture Co. (7.8%). www.xanodyne.com

Leave a Reply

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget